Lipopolysaccharide inhibits osteoblast formation and receptor activator of nuclear factor-κB ligand degradation via autophagy inhibition
Endocrine Journal · 2024
DOI: 10.1507/endocrj.ej23-0484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Journal, 2024. Verfasst von Huaizhi Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Minimally Invasive Spinal Surgery, The Affiliated Hospital of Putian University, Putian 351100, Fujian, China. Hauptthemen laut MEDLINE: Lipopolysaccharides, Osteoblasts, Autophagy, RANK Ligand. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Minimally Invasive Spinal Surgery, The Affiliated Hospital of Putian University, Putian 351100, Fujian, China.
- Department of Orthopaedics, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, Fujian, China.
Zitieren
APA
Zhang, H., Lin, J., Chen, X., Dai, J., & Lin, H. (2024). Lipopolysaccharide inhibits osteoblast formation and receptor activator of nuclear factor-κB ligand degradation via autophagy inhibition. Endocrine Journal. https://doi.org/10.1507/endocrj.ej23-0484
Vancouver
Zhang H, Lin J, Chen X, Dai J, Lin H. Lipopolysaccharide inhibits osteoblast formation and receptor activator of nuclear factor-κB ligand degradation via autophagy inhibition. Endocrine Journal. 2024. doi:10.1507/endocrj.ej23-0484
BibTeX
@article{Zhang2024,
author = {Zhang, Huaizhi and Lin, Jianhua and Chen, Xu and Dai, Jianhui and Lin, Haibin},
title = {Lipopolysaccharide inhibits osteoblast formation and receptor activator of nuclear factor-κB ligand degradation via autophagy inhibition},
journal = {Endocrine Journal},
year = {2024},
doi = {10.1507/endocrj.ej23-0484}
}
EUVIMED